AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ALVO · NASDAQ · Drug Manufacturers - Specialty & Generic

Alvotech (ALVO)

Develops and manufactures biosimilar medicines through an integrated platform and partner network.

$5.84

After hours−0.02 (−0.26%)

At close$5.86(−0.43%)

In millions of USD, except per-share figures

In millions	Q3 FY23Aug 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	18	53	37	199	103	151	133	173	114	166	106	106
Cost of revenue	37	56	20	45	40	80	65	74	35	61	46	52
Gross profit	−19	−3	17	154	63	71	67	99	79	105	60	54
	70	76	65	62	50	57	57	81	78	57	50	65
Research & development	53	58	50	48	34	40	38	55	52	40	25	22
	17	18	15	14	17	15	19	27	26	20	26	44
General & administrative	17	18	15	14	17	15	19	27	26	20	0	0
Other expenses	0	0	0	0	0	2	0	0	0	−2	0	0
Operating income	−89	−79	−48	92	13	13	11	18	1	48	10	−12
	−117	−230	−177	−15	−37	−58	83	−9	−7	−9	−9	−55
Interest income	0	0	1	80	77	−154	126	23	21	28	33	0
Interest expense	44	69	184	42	91	−159	36	37	36	41	41	41
Other non-operating income	67	161	−7	116	−117	142	−118	−25	−29	143	−32	0
Income before tax	−206	−309	−225	77	−25	−44	93	9	−6	40	1	−67
Income tax expense	−17	−32	−6	12	−13	23	−16	−23	−1	148	0	0
Net income from continuing operations	−188	−277	−219	65	−11	−67	110	32	−5	−109	1	−67
Net income	−188	−277	−219	65	−11	−67	110	32	−5	−109	1	−67
EPS, basic	−$0.70	−$1.04	−$0.82	$0.25	−$0.04	−$0.22	$0.39	$0.11	−$0.02	−$0.38	$0.00	−$0.19
EPS, diluted	−$0.70	−$1.04	−$0.82	$0.25	−$0.04	−$0.22	$0.35	$0.10	−$0.02	−$0.43	$0.00	−$0.19
Weighted average shares, basic	267	267	267	259	280	302	281	281	300	279	330	357
Weighted average shares, diluted	267	267	267	259	280	302	313	313	300	279	330	357
EBITDA	−149	−234	−34	−17	138	−120	137	52	33	−85	52	−2
Depreciation & amortization	7	7	7	8	8	8	8	9	2	10	10	10
EBIT	−156	−240	−41	−24	130	−128	129	43	30	−95	42	−12